SHANGHAI, CHINA kanye ne-CAMBRIDGE, MASSACHUSETTS, US, Okthoba 27, 2022 - I-JW Therapeutics (HKEX: 2126), inkampani ezimele nentsha ye-biotechnology egxile ekuthuthukiseni, ekukhiqizeni, nasekuthengiseni imikhiqizo ye-cell immunotherapy, kanye namashumi ayisikhombisa I-Bio (NASDAQ: TSVT), inkampani ehamba phambili ye-immuno-oncology cell therapy, namuhla imemezele umfelandawonye wamasu wokusungula inkundla yokuhumusha kanye neyomtholampilo yokuthuthukiswa kokwelashwa kwamaseli eklanyelwe ukuhlola ngokushesha okukhulu. I-T cell-based immunotherapy imikhiqizo esezweni laseShayina, eHong Kong (eChina), naseMacao (eChina).
Ukugxila kokuqala kokusebenzisana kuwuhlelo lwe-2seventy lwe-MAGE-A4 TCR kumathumba aqinile, oluthuthukiswa njengengxenye yokubambisana ne-Regeneron. I-MAGE-A4 iyilungu lomndeni wakwa-MAGE wama-antigens omdlavuza-testis ovezwa ngenani lezinhlobo eziqinile zesimila. Uhlelo luklanyelwe ukuthuthukisa Ukwelashwa kwe-T cell receptor (TCR). ekwelapheni i-MAGE-A4 positive izimila eziqinile.
Ungahle uthande ukufunda: Ukwelashwa kwe-CAR T-Cell eChina
"Siyajabula ukusebenzisana ne-2Seventy bio ukuthuthukisa ngokubambisana uhlelo lwe-MAGE-A4 TCR kanye nezinye izimpahla ezingase zibe khona e-China," kusho uDkt. Mark J. Gilbert, Isikhulu Esiyinhloko Sezokwelapha se-JW Therapeutics. “I-2Seventy iyinkampani esezingeni eliphezulu yokwelapha ngamaseli enobuchwepheshe obuphambili kanye nethimba elinolwazi olunzulu. Lo mfelandawonye uzothuthukisa amakhono ethu adidiyelwe asezingeni lomhlaba, okuhlanganisa ucwaningo lokuhumusha kanye nokuthuthukiswa komtholampilo, futhi sibheke phambili ekusheshiseni ukuthuthukiswa kwemikhiqizo eminingi ye-cell immunotherapy enenani eliphumelelayo lokwelapha ukusiza iziguli eziningi ezinomdlavuza e-China kanye nasemhlabeni wonke.
"Inzuzo yangempela yesiguli yalokhu kubambisana ilele ekukwazini ukusungula amakhono engeziwe okuhlola ngokushesha, ukufunda, nokuqhubekisela phambili izinhlelo zethu ezintsha zelashwa ngamaseli," kusho uSteve Bernstein, isikhulu sezokwelapha, i-2Seventy bio. “I-JW Therapeutics inokuqonda okubanzi ngezidingo zezokwelapha ezingahlangatshezwanga zabantu kanye nenqubo yezindaba zokulawula eShayina, kanye nezindlela zokuthuthukiswa komtholampilo. Ithuba lokuhlanganisa izindawo zethu ezihlukile zokuhlangenwe nakho ukuze sakhe inkundla ehlukene isekela umgomo wethu wokuletha izindlela zokwelapha ezintsha ezigulini ngokushesha ngangokunokwenzeka.”
Ungahle uthande ukufunda: Izindleko zokwelashwa kwe-CAR T-Cell e-China
Ngaphansi kwemibandela yesivumelwano, i-2seventini izonikeza i-JW Therapeutics ilayisensi yokwelashwa kwamaseli i-MAGE-A4 ezweni laseChina, eHong Kong (China), naseMacao (China). I-JW Therapeutics izobhekana nentuthuko, ukukhiqiza, kanye nokuhweba ngaphakathi kweChina. I-2seventy ifaneleka ukuthola ama-milestone kanye nezinzuzo ngenzuzo yomkhiqizo e-China. Ukwengeza, i-2seventini ingase isebenzise idatha yokuqala yomtholampilo ekhiqizwa ngaphansi kokubambisana ukuze isekele intuthuko kwezinye izindawo. Ukuvalwa kokuthengiselana kuzoncika ekugunyazweni kwabanikazi bamasheya be-JW Therapeutics kanye neminye imibandela yokuvala evamile.
Mayelana nohlelo lwe-MAGE-A4
I-MAGE-A4 iyilungu lomndeni wakwa-MAGE wama-antigens omdlavuza-testis ovezwa ngenani lezinhlobo eziqinile zesimila. Uhlelo lwethu lisebenzisa i-TCR enamandla kakhulu etholwe ekuhlanganyeleni kwethu kwe-MediGene
ebona ama-peptide e-MAGE-A4 ethulwe yi-HLA futhi athuthukise amandla alawa maseli e-T aqondiswe kabusha kusetshenziswa ubuchwepheshe bethu be-CTBR12 TGF-beta "flip" receptor, obuguqula imiphumela ye-immunosuppressive ye-TGF-beta ibe isignali yokusebenzisa amaseli T. . I-Regeneron kanye ne-2seventy bio bathuthukisa ngokuhlanganyela uhlelo ngaphansi kokubambisana kwabo okungenwe kukho ngo-2018.
Ungahle uthande ukufunda: Ukwelashwa kwe-CAR T-Cell ye-myeloma eminingi e-China
Mayelana ne-JW Therapeutics
I-JW Therapeutics (HKEX: 2126) yinkampani ezimele nentsha ye-biotechnology egxile ekuthuthukiseni, ekukhiqizeni, nasekuhwebeni kwemikhiqizo ye-cell immunotherapy, futhi izibophezele ekubeni umholi wokuqamba kabusha ku-cell immunotherapy. Yasungulwa ngo-2016, i-JW Therapeutics yakhe inkundla esezingeni lomhlaba yokuthuthukiswa komkhiqizo ku-cell immunotherapy, kanye nepayipi lomkhiqizo elimboza kokubili izifo ze-hematological kanye nezimila eziqinile. I-JW Therapeutics izibophezele ekuletheni impumelelo kanye nekhwalithi yemikhiqizo ye-cell immunotherapy kanye nethemba lokwelapha iziguli zaseShayina nasemhlabeni wonke, futhi iholele ekuthuthukisweni okunempilo nokujwayelekile kweziguli. I-China cell immunotherapy imboni.
Mayelana ne-2Seventini bio
Igama lethu, 2seventini bio, libonisa ukuthi kungani senza esikwenzayo - ISIKHATHI. Umdlavuza udla isikhathi, futhi umgomo wethu uwukusebenza ngesivinini esikhulu sokuhumusha umcabango womuntu ube yisenzo—amamayela angu-270 ngehora—ukuze sinikeze abantu esibasebenzelayo isikhathi esengeziwe. Sakha inkampani ehamba phambili ye-immuno-oncology cell therapy, egxile ekutholeni nasekuthuthukiseni izindlela zokwelapha ezintsha eziphazamisa ngempela isimo sokwelapha umdlavuza.
Ngokuqonda okujulile kokusabela komzimba womuntu kumaseli wesimila kanye nendlela yokuhumusha ukwelashwa kwamangqamuzana kusebenze, sisebenzisa lolu lwazi ukuze silethe izindlela zokwelapha zamaselula esizukulwaneni esilandelayo ezigxile ezinhlobonhlobo eziningi zezifo ze-hematological, okuhlanganisa neyokuqala egunyazwe yi-FDA. I-CAR T cell therapy ye-myeloma eminingi, kanye nezimila eziqinile. Ucwaningo lwethu nentuthuko kugxile ekuletheni izindlela zokwelapha eziklanywe ngenhloso “yokucabanga” ngobuhlakani nangokushesha ukwedlula lesi sifo. Okubalulekile, sihlala sigxile ekufezeni le migomo ngokuhlala siqotho futhi siyiqiniso “kungani” kwethu kanye nokugcina abantu bethu namasiko engqondo nsuku zonke.
Izitatimende Ezibheke Phambili ze-JW Therapeutics
Izitatimende ezibheke phambili zisekelwe kulokho abaphathi abakulindele nezinkolelo zabo futhi zingaphansi kwenani lezingozi nokungaqiniseki okungabangela imiphumela yangempela ukuthi ihluke ngokubonakalayo kuleyo echazwe. Izingozi ezinkulu nokungaqiniseki, kufaka phakathi lokho okuxoxwe ngakho ngezansi futhi kuchazwe ngokugcwele emibikweni ye-Hong Kong Exchanges and Clearing Limited (HKEX) efakwe yinkampani. Ngaphandle kwalapho kuphawulwe ngenye indlela, inkampani inikeza lolu lwazi kusukela ngosuku eyalumemezela ngalo, futhi iwuchitha ngokusobala noma yimuphi umsebenzi wokubuyekeza ulwazi oluqukethwe ezindabeni nolwazi olufanele, noma ukunikeza noma iyiphi incazelo.
Ungahle uthande ukufunda: I-FUCASO yokwelashwa kwe-myeloma eminingi
Inothi Lesexwayiso Mayelana Nezitatimende Ezibheke Phambili ze-2seventini bio
Lokhu kukhululwa kuqukethe "izitatimende ezibheke phambili" ngaphakathi kwencazelo ye-Private Securities Litigation Reform Act of 1995. Lezi zitatimende zifaka, kodwa azikhawulelwe kulokhu: izitatimende mayelana nezinhlelo zethu, amasu, izikhathi kanye nesikulindele mayelana nokuthuthukiswa, ukukhiqiza noma ukuthengiswa kwamakhandidethi emikhiqizo yethu, okuhlanganisa imiphumela kanye nesikhathi esilindelekile sezivivinyo zemitholampilo eziqhubekayo nezihleliwe zabakhandidethi bomkhiqizo wethu e-China kanye nesivinini esingalethela ngaso labo makhandidethi izivivinyo zokwelashwa; izitatimende mayelana nokusebenza ngempumelelo kanye nezinzuzo zokwelashwa ezibonwayo zabakhandi bemikhiqizo yethu kanye nezinkomba ezingaba khona, amathuba emakethe kanye nesidingo salokho; izitatimende mayelana nezinhlelo zamasu ze-2seventini bio kanye namathuba okuthuthukiswa kwebhizinisi okungenzeka; izitatimende mayelana nesimo sezimali senkampani, neminye imiphumela yezezimali yesikhathi esizayo; kanye nezitatimende mayelana nekhono lethu lokwenza izinto eziza kuqala kithi.
Noma yiziphi izitatimende ezibheke phambili kulokhu kukhululwa kwabezindaba zisekelwe kulokho okulindelwe abaphathi nezinkolelo zamanje futhi zingaphansi kwenani lezingozi, ukungaqiniseki kanye nezici ezibalulekile ezingabangela izehlakalo zangempela noma imiphumela yehluke ngokubonakalayo kuleyo evezwe noma eshiwo yinoma yikuphi ukubheka phambili. izitatimende eziqukethwe kulokhu kukhululwa kwabezindaba, okuhlanganisa, ngaphandle komkhawulo; ubungozi bokuthi izinhlelo zethu mayelana nokuthuthukiswa komtholampilo kanye nokwelashwa kanye nokugunyazwa ngokomthetho kwabantu abakhetha umkhiqizo wethu kungase kungafinyelelwa ngempumelelo emugqeni wesikhathi ohleliwe, noma nhlobo.
Ukuze uthole ingxoxo ngezinye izingozi nokungaqiniseki, nezinye izici ezibalulekile, noma yiziphi ezingabangela imiphumela yethu yangempela ukuthi ihluke kuleyo equkethwe ezitatimendeni ezibheke phambili, bheka isigaba esithi “Izici Zobungozi” embikweni wethu wonyaka weFomu 10- K yonyaka ophele ngomhla ka-31 Disemba 2021, njengoba kungezwe futhi/noma kulungiswe umbiko wethu wakamuva weQuarterly Report on Form 10-Q kanye nanoma yikuphi okunye ukugcwalisa esikwenzile noma esizokwenza ne-Securities and Exchange Commission esikhathini esizayo.
Lonke ulwazi kulokhu kukhishwa kwabezindaba lungosuku lokukhululwa, futhi i-2seventy bio ayinawo umsebenzi wokubuyekeza lolu lwazi ngaphandle uma kudingwa umthetho.
